Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
- Pfizer
- DESY
- BioNTech SE
- CareerPhysician, LLC
- Columbia University Medical Center
- Faculté de biologie et de médecine de Lausanne
- Miami Miller School of Medicine - Desai Sethi Urology and Sylvester Comprehensive Cancer Center
- National Human Genome Research Institute, NIH
- National Institutes of Health/National Library of Medicine
- Thomas Jefferson University Department of Biochemistry
- Xinxiang Medical University Yazhouwan National Laboratory
- Yazhouwan National Laboratory
- 2 more »
- « less
-
Field
-
other divisions of Pfizer, and potentially from external partners. MINIMUM QUALIFICATIONS Ph.D. in Immunology or Computational Biology with a focus on the immune system, or related fields. 5+ years
-
Xinxiang Medical University Yazhouwan National Laboratory | National Physical Laboratory, Delhi | India | about 1 month ago
, forensic medicine, biology, biomedical engineering, Marxist theory, management, psychology, English, physical education and sport science, etc. Categories1:Top-notch Talents Requirements:Academic experts and
-
and a 7T Clinical Magnet and 9.4T Animal Magnet dedicated exclusively to research endeavors. Outstanding Research Cores and Shared Resources including, but not limited to, Imaging, Structural Biology
-
(examples, CNS regulation of energy balance, muscle or adipose metabolism/function). Expertise in cell biology and physiology with emphasis on metabolism and signaling pathways is essential. Experience
-
sciences, cell biology, pharmacology, or related discipline. Experience in the design, execution, and analysis of cellular, molecular, and/or biochemical assays focused on understanding drug transport and
-
Miami Miller School of Medicine - Desai Sethi Urology and Sylvester Comprehensive Cancer Center | Miami, Florida | United States | 2 months ago
durable clinical benefits. Applicants should have a primary interest in the fundamental mechanisms of human biology, biochemistry, metabolism, or genetics, with some relevance to genitourinary cancers